NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癌症醫療的流式細胞技術的全球市場 (2021-2031年):市場預測 (各產品類型、技術、癌症的種類、用途、終端用戶)、各國分析 (16個國家)、競爭分析

Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

出版商 BIS Research Inc. 商品編碼 1009534
出版日期 內容資訊 英文 257 Pages
商品交期: 最快1-2個工作天內
價格
癌症醫療的流式細胞技術的全球市場 (2021-2031年):市場預測 (各產品類型、技術、癌症的種類、用途、終端用戶)、各國分析 (16個國家)、競爭分析 Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031
出版日期: 2021年06月03日內容資訊: 英文 257 Pages
簡介

癌症醫療的流式細胞技術的市場規模在預測期間內預計以12.02%的年複合成長率發展,成長到2031年52億5000萬美元的規模。

骨髓惡性腫瘤的發病率上升,對個體化治療和精密醫療的消費者的意識高漲等要素促進該市場的成長。

本報告提供全球癌症醫療的流式細胞技術的市場調查,市場定義和概要,法律規章上架構,市場成長的各種影響因素分析,市場規模的變化、預測,產品類型、技術、癌症的種類、用途、終端用戶、地區等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

摘要整理

第1章 產品定義

第2章 市場範圍

第3章 調查手法

第4章 市場概要

第5章 產業考察

  • 概要
  • 法律上的必要條件、架構:美國
  • 法律上的必要條件、架構:歐洲
  • 法律上的必要條件、架構:亞太地區

第6章 市場動態

  • 概要
  • 影響分析
  • 市場推動因素
  • 市場抑制因素
  • 市場機會

第7章 競爭情形

  • 產品銷售
  • 聯盟、合作
  • 收購
  • 產品的認證、事業的擴大
  • 成長佔有率分析
  • MRD試驗技術競爭分析

第8章 市場分析、預測:各產品類型

  • 概要
  • 化驗、套件
  • 設備
  • 試劑、消耗品
  • 軟體

第9章 市場分析、預測:各技術

  • 概要
  • 細胞為基礎
  • 以微珠為基礎

第10章 市場分析、預測:癌症的各類型

  • 概要
  • 骨髓惡性腫瘤
    • 淋巴瘤
    • 白血病
    • 骨髓瘤
    • 其他
  • 固態腫瘤
    • 乳癌
    • 前列腺癌
    • 大腸癌
    • 肺癌
    • 其他

第11章 市場分析、預測:各用途

  • 概要
  • 轉化研究
  • 臨床應用
    • 篩檢、診斷
    • 治療監測

第12章 市場分析、預測:各終端用戶

  • 概要
  • 診斷實驗室
  • 醫院、診所
  • 學術、研究機關
  • 其他

第13章 市場分析、預測:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他地區

第14章 企業簡介

  • Agilent Technologies, Inc.
  • Apogee Flow Systems Ltd.
  • Becton, Dickinson and Company
  • bioAffinity Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Cytek Biosciences
  • Cytognos, S.L.
  • Danaher Corporation
  • Miltenyi Biotec B.V. & Co. KG
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • NeoGenomics Laboratories, Inc.
  • Sony Corporation
  • Thermo Fisher Scientific Inc.
目錄
Product Code: BHP1070SA

Global Flow Cytometry in Oncology Market to Reach $5.25 Billion by 2031

Market Report Coverage - Flow Cytometry in Oncology

Market Segmentation

  • Product Type - Assays and Kits, Instruments, Reagents and Consumables, and Software
  • Technology - Cell-Based and Bead-Based
  • Type of Cancer - Hematological Malignancies (Lymphoma, Leukemia, Myeloma, and Other Hematological Malignancies) and Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, and Other Solid Tumors)
  • Application - Translational Research and Clinical Applications (Screening and Diagnostics, and Treatment Monitoring)
  • End User - Diagnostic Laboratories, Hospitals and Healthcare Centers, Academic and Research Institutions, and Other End Users

Regional Segmentation

  • North America - U.S., and Canada
  • Europe - Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

Market Growth Drivers

  • Rising Incidence of Hematological Malignancies
  • Increasing Fund Infusions for Hematological Malignancies
  • Growing Consumer Awareness for Tailored Therapy and Precision Medicine

Market Challenges

  • False Negatives and Positives
  • Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD Assessment

Market Opportunities

  • Technological Evolution in the Field of Flow Cytometry
  • Growth in Solid Tumor Applications of Flow Cytometry

Key Surgical Instrument Tracking Devices Companies Profiled

Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytek Biosciences, Cytognos, S.L., Danaher Corporation, Miltenyi Biotec B.V. & Co. KG, Laboratory Corporation of America Holdings, Luminex Corporation, NeoGenomics Laboratories, Inc., Sony Corporation, and Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

  • How is flow cytometry revolutionizing the field of oncology?
  • What are the major market drivers, challenges, and opportunities in the global flow cytometry in oncology market?
  • What are the underlying structures resulting in the emerging trends within the global flow cytometry in oncology market?
  • How is the COVID-19 pandemic impacting the global flow cytometry in oncology ecosystem?
  • What are the key development strategies that are being implemented by the major players in order to sustain the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of flow cytometry in the field of oncology?
  • What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
  • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
    • Product Type (assays and kits, instruments, reagents and consumables, and software)
    • Technology (cell-based and bead-based)
    • Type of Cancer (hematological malignancies and solid tumor)
    • Application (translational research and clinical applications)
    • End User (diagnostic laboratories, hospitals and healthcare clinics, academic and research institutions, and other end users)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • What are the growth opportunities for the companies in the region of their operation?
  • Who are the leading players with significant offerings in the global flow cytometry in oncology market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

Our healthcare experts have found flow cytometry in oncology industry to be one of the most rapidly evolving and dynamic markets. The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031. The market is driven by certain factors, including rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine.

The market is favored by the developments in the field of cancer diagnostic testing and its attributes such as flow cytometry. Currently, the flow cytometry in oncology industry is witnessing an upsurge due to the rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine. Additionally, high adoption of flow cytometry instruments by the end users to conduct cancer diagnosis and therapeutic monitoring are some of the critical factors that are expected to bolster the market growth.

Furthermore, biotechnology companies are focusing on the development of robust flow cytometry solutions for a wide range of applications, including translational research and clinical applications, to support researchers and physicians in unraveling insights pertaining to cellular alterations.

Within the research report, the market is segmented on the basis of product type, technology, type of cancer, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of cases associated with cancer, particularly hematological malignancies, has created a buzz among the biotechnology companies to further invest in the development of cancer diagnostic solutions such as flow cytometry, further aiding physicians to offer value-based therapeutic outcomes to patients. Becton, Dickinson and Company has been a pioneer in this field and has been a significant competitor in this market due to the presence of a diverse product portfolio and intense market penetration.

On the basis of region, in 2020, North America held the largest share of the flow cytometry in oncology market due to high infusion of funding from the government organizations for conducting cancer research, growing incidence and prevalence of cancer, growing awareness about precision medicine, and increasing awareness about early cancer detection, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Flow Cytometry in Oncology Market: Research Methodology
  • 3.2 Data Sources
    • 3.2.1 Primary Data Sources
    • 3.2.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Criteria for Company Profiling

4 Market Overview

  • 4.1 Market Definition
  • 4.2 Application of Flow Cytometry in Oncology (Hematological vs. Solid Tumors)
  • 4.3 Market Footprint and Growth Potential
  • 4.4 COVID-19 Impact: Global Flow Cytometry in Oncology Market

5 Industry Insights

  • 5.1 Overview
  • 5.2 Legal Requirements and Framework in U.S.
  • 5.3 Legal Requirements and Framework in Europe
  • 5.4 Legal Requirements and Framework in Asia-Pacific
    • 5.4.1 China
    • 5.4.2 Japan

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
  • 6.3 Market Drivers
    • 6.3.1 Rising Incidence of Hematological Malignancies
    • 6.3.2 Increasing Fund Infusions for Hematological Malignancies
    • 6.3.3 Growing Consumer Awareness for Tailored Therapy and Precision Medicine
  • 6.4 Market Restraints
    • 6.4.1 False Negatives and Positives
    • 6.4.2 Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD Assessment
  • 6.5 Market Opportunities
    • 6.5.1 Technological Evolution in the Field of Flow Cytometry
      • 6.5.1.1 Emergence of Multiparametric Flow Cytometry for Hematologic Malignancies
      • 6.5.1.2 Growing Focus on Next-Generation Flow Cytometry
    • 6.5.2 Growth in Solid Tumor Applications of Flow Cytometry

7 Competitive Landscape

  • 7.1 Product Launches
  • 7.2 Synergistic Activities
  • 7.3 Acquisitions
  • 7.4 Product Approvals and Business Expansion Activities
  • 7.5 Market Share Analysis, 2019-2020
  • 7.6 Growth Share Analysis
    • 7.6.1 Growth Share Analysis (by Company)
    • 7.6.2 Growth Share Analysis (by Technology)
    • 7.6.3 Growth Share Analysis (by Type of Cancer)
    • 7.6.4 Growth Share Analysis (by Application)
  • 7.7 Competitive Assessment of Different Technologies Utilized for MRD Testing

8 Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020-2031

  • 8.1 Overview
  • 8.2 Assays and Kits
  • 8.3 Instruments
  • 8.4 Reagents and Consumables
  • 8.5 Software

9 Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020-2031

  • 9.1 Overview
  • 9.2 Cell-Based
  • 9.3 Bead-Based

10 Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031

  • 10.1 Overview
  • 10.2 Hematological Malignancies
    • 10.2.1 Lymphoma
    • 10.2.2 Leukemia
    • 10.2.3 Myeloma
    • 10.2.4 Other Hematological Malignancies
    • 10.2.5 Global Flow Cytometry Market for Hematological Malignancies (by Technology)
  • 10.3 Solid Tumors
    • 10.3.1 Breast Cancer
    • 10.3.2 Prostate Cancer
    • 10.3.3 Colorectal Cancer (CRC)
    • 10.3.4 Lung Cancer
    • 10.3.5 Other Solid Tumors
    • 10.3.6 Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology)

11 Global Flow Cytometry in Oncology Market (by Application), $Million, 2020-2031

  • 11.1 Overview
  • 11.2 Translational Research
  • 11.3 Clinical Applications
    • 11.3.1 Screening and Diagnostics
    • 11.3.2 Treatment Monitoring

12 Global Flow Cytometry in Oncology Market (by End User), $Million, 2020-2031

  • 12.1 Overview
  • 12.2 Diagnostic Laboratories
  • 12.3 Hospitals and Healthcare Clinics
  • 12.4 Academic and Research Institutions
  • 12.5 Other End Users

13 Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 U.S.
    • 13.2.2 Canada
    • 13.2.3 North America Flow Cytometry in Oncology Market (by Type of Cancer)
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 U.K.
    • 13.3.3 France
    • 13.3.4 Italy
    • 13.3.5 Spain
    • 13.3.6 Netherlands
    • 13.3.7 Rest-of-Europe
    • 13.3.8 Europe Flow Cytometry in Oncology Market (by Type of Cancer)
  • 13.4 Asia-Pacific (APAC)
    • 13.4.1 China
    • 13.4.2 Japan
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 South Korea
    • 13.4.6 Singapore
    • 13.4.7 Rest-of-Asia-Pacific (RoAPAC)
    • 13.4.8 Asia-Pacific Flow Cytometry in Oncology Market (by Type of Cancer)
  • 13.5 Latin America (LATAM0
    • 13.5.1 Brazil
    • 13.5.2 Mexico
    • 13.5.3 Rest-of-Latin America (RoLA)
    • 13.5.4 Latin America Flow Cytometry in Oncology Market (by Type of Cancer)
  • 13.6 Rest-of-the-World (RoW)
    • 13.6.1 Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer)

14 Company Profiles

  • 14.1 Overview
  • 14.2 Agilent Technologies, Inc.
    • 14.2.1 Company Overview
    • 14.2.2 Role of Agilent Technologies, Inc. in the Global Flow Cytometry in Oncology Market
    • 14.2.3 Financials
    • 14.2.4 Key Insights About Financial Health of the Company
    • 14.2.5 SWOT Analysis
  • 14.3 Apogee Flow Systems Ltd.
    • 14.3.1 Company Overview
    • 14.3.2 Role of Apogee Flow Systems Ltd. in the Global Flow Cytometry in Oncology Market
    • 14.3.3 SWOT Analysis
  • 14.4 Becton, Dickinson and Company
    • 14.4.1 Company Overview
    • 14.4.2 Role of Becton, Dickinson and Company in the Global Flow Cytometry in Oncology Market
    • 14.4.3 Financials
    • 14.4.4 Key Insights About Financial Health of the Company
    • 14.4.5 SWOT Analysis
  • 14.5 bioAffinity Technologies, Inc.
    • 14.5.1 Company Overview
    • 14.5.2 Role of bioAffinity Technologies, Inc. in the Global Flow Cytometry in Oncology Market
    • 14.5.3 SWOT Analysis
  • 14.6 Bio-Rad Laboratories, Inc.
    • 14.6.1 Company Overview
    • 14.6.2 Role of Bio-Rad Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
    • 14.6.3 Financials
    • 14.6.4 Key Insights About Financial Health of the Company
    • 14.6.5 SWOT Analysis
  • 14.7 Bio-Techne Corporation
    • 14.7.1 Company Overview
    • 14.7.2 Role of Bio-Techne Corporation in the Global Flow Cytometry in Oncology Market
    • 14.7.3 Financials
    • 14.7.4 Key Insights About Financial Health of the Company
    • 14.7.5 SWOT Analysis
  • 14.8 Cytek Biosciences
    • 14.8.1 Company Overview
    • 14.8.2 Role of Cytek Biosciences in the Global Flow Cytometry in Oncology Market
    • 14.8.3 SWOT Analysis
  • 14.9 Cytognos, S.L.
    • 14.9.1 Company Overview
    • 14.9.2 Role of Cytognos, S.L. in the Global Flow Cytometry in Oncology Market
    • 14.9.3 SWOT Analysis
  • 14.1 Danaher Corporation
    • 14.10.1 Company Overview
    • 14.10.2 Role of Danaher Corporation in the Global Flow Cytometry in Oncology Market
    • 14.10.3 Financials
    • 14.10.4 Key Insights About Financial Health of the Company
    • 14.10.5 SWOT Analysis
  • 14.11 Miltenyi Biotec B.V. & Co. KG
    • 14.11.1 Company Overview
    • 14.11.2 Role of Miltenyi Biotec B.V. & Co. KG in the Global Flow Cytometry in Oncology Market
    • 14.11.3 SWOT Analysis
  • 14.12 Laboratory Corporation of America Holdings
    • 14.12.1 Company Overview
    • 14.12.2 Role of Laboratory Corporation of America Holdings in the Global Flow Cytometry in Oncology Market
    • 14.12.3 Financials
    • 14.12.4 SWOT Analysis
  • 14.13 Luminex Corporation
    • 14.13.1 Company Overview
    • 14.13.2 Role of Luminex Corporation in the Global Flow Cytometry in Oncology Market
    • 14.13.3 Financials
    • 14.13.4 Key Insights About Financial Health of the Company
    • 14.13.5 SWOT Analysis
  • 14.14 NeoGenomics Laboratories, Inc.
    • 14.14.1 Company Overview
    • 14.14.2 Role of NeoGenomics Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
    • 14.14.3 Financials
    • 14.14.4 Key Insights about Financial Health of the Company
    • 14.14.5 SWOT Analysis
  • 14.15 Sony Corporation
    • 14.15.1 Company Overview
    • 14.15.2 Role of Sony Corporation in the Global Flow Cytometry in Oncology Market
    • 14.15.3 Financials
    • 14.15.4 Key Insights About Financial Health of the Company
    • 14.15.5 SWOT Analysis
  • 14.16 Thermo Fisher Scientific Inc.
    • 14.16.1 Company Overview
    • 14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Flow Cytometry in Oncology Market
    • 14.16.3 Financials
    • 14.16.4 Key Insights About Financial Health of the Company
    • 14.16.5 SWOT Analysis

List of Tables

  • Table 6.1: Likert Scale
  • Table 6.2: Impact Analysis of Market Drivers
  • Table 6.3: Impact Analysis of Market Restraints

List of Figures

  • Figure 1: Prevalence of Hematological Malignancies in the U.S., 2013-2016
  • Figure 2: National Cancer Institute (NCI) of the U.S., Fiscal Budget Year-on-Year, 2013-2018
  • Figure 3: Impact Analysis of Market Drivers and Market Challenges on Global Flow Cytometry in Oncology Market
  • Figure 4: Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
  • Figure 5: Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
  • Figure 6: Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
  • Figure 7: Global Flow Cytometry in Oncology Market (by Application), $Million, 2020 and 2031
  • Figure 8: Global Flow Cytometry in Oncology Market (by End User), $Million, 2020 and 2031
  • Figure 9: Global Flow Cytometry in Oncology: Market Snapshot
  • Figure 2.1: Market Segmentation of Global Flow Cytometry in Oncology Market
  • Figure 3.1: Global Flow Cytometry in Oncology Market: Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Global Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 4.2: Global Flow Cytometry in Oncology Market: COVID-19 Impact
  • Figure 6.1: Global Incidence and Mortality Rate for Individual Hematological Conditions, 2016
  • Figure 6.2: Estimated New Cases of Hematological Cancer, 2020
  • Figure 7.1: Share of Key Developments and Strategies, January 2017-May 2021
  • Figure 7.2: Number of Product Launches (by Company), January 2017-May 2021
  • Figure 7.3: Share of Synergistic Activities (by Company), January 2017-May 2021
  • Figure 7.4: Share of Acquisitions (by Company), January 2017-May 2021
  • Figure 7.5: Market Share Analysis for Global Flow Cytometry in Oncology Market, $Million, 2019 and 2020
  • Figure 7.6: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Company), 2020
  • Figure 7.7: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Technology), 2020-2031
  • Figure 7.8: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Type of Cancer), 2020-2031
  • Figure 7.9: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Application), 2020-2031
  • Figure 7.10: Comparative Assessment of Technologies Used in MRD Testing
  • Figure 8.1: Global Flow Cytometry in Oncology Market (by Product Type)
  • Figure 8.2: Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
  • Figure 8.3: Global Flow Cytometry in Oncology Market (Assays and Kits), $Million, 2020-2031
  • Figure 8.4: Global Flow Cytometry in Oncology Market (Instruments), $Million, 2020-2031
  • Figure 8.5: Global Flow Cytometry in Oncology Market (Reagents and Consumables), $Million, 2020-2031
  • Figure 8.6: Global Flow Cytometry in Oncology Market (Software), $Million, 2020-2031
  • Figure 9.1: Global Flow Cytometry in Oncology Market (by Technology)
  • Figure 9.2: Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
  • Figure 9.3: Global Flow Cytometry in Oncology Market (Cell-Based), $Million, 2020-2031
  • Figure 9.4: Global Flow Cytometry in Oncology Market (Bead-Based), $Million, 2020-2031
  • Figure 10.1: Global Flow Cytometry in Oncology Market (by Type of Cancer)
  • Figure 10.2: Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
  • Figure 10.3: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020-2031
  • Figure 10.4: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020 and 2031
  • Figure 10.5: Global Flow Cytometry in Oncology Market (Lymphoma), $Million, 2020-2031
  • Figure 10.6: Global Flow Cytometry in Oncology Market (Leukemia), $Million, 2020-2031
  • Figure 10.7: Global Flow Cytometry in Oncology Market (Myeloma), $Million, 2020-2031
  • Figure 10.8: Global Flow Cytometry in Oncology Market (Other Hematological Malignancies), $Million, 2020-2031
  • Figure 10.9: Global Flow Cytometry in Oncology Market for Hematological Malignancies (by Technology), $Million, 2020-2031
  • Figure 10.10: Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020-2031
  • Figure 10.11: Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020 and 2031
  • Figure 10.12: Global Flow Cytometry in Oncology Market (Breast Cancer), $Million, 2020-2031
  • Figure 10.13: Global Flow Cytometry in Oncology Market (Prostate Cancer), $Million, 2020-2031
  • Figure 10.14: Global Flow Cytometry in Oncology Market (Colorectal Cancer), $Million, 2020-2031
  • Figure 10.15: Global Flow Cytometry in Oncology Market (Lung Cancer), $Million, 2020-2031
  • Figure 10.16: Global Flow Cytometry in Oncology Market (Other Solid Tumors), $Million, 2020-2031
  • Figure 10.17: Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology), $Million, 2020-2031
  • Figure 11.1: Global Flow Cytometry in Oncology Market (by Application)
  • Figure 11.2: Global Flow Cytometry in Oncology Market (by Application), $Million, 2020-2031
  • Figure 11.3: Global Flow Cytometry in Oncology Market (Translational Research), $Million, 2020-2031
  • Figure 11.4: Global Flow Cytometry in Oncology Market (by Clinical Applications), $Million, 2020 and 2031
  • Figure 11.5: Global Flow Cytometry in Oncology Market (Screening and Diagnostics), $Million, 2020-2031
  • Figure 11.6: Global Flow Cytometry in Oncology Market (Treatment Monitoring), $Million, 2020-2031
  • Figure 12.1: Global Flow Cytometry in Oncology Market (by End User)
  • Figure 12.2: Global Flow Cytometry in Oncology Market (by End User), $Million, 2020-2031
  • Figure 12.3: Global Flow Cytometry in Oncology Market (Diagnostic Laboratories), $Million, 2020-2031
  • Figure 12.4: Global Flow Cytometry in Oncology Market (Hospitals and Healthcare Clinics), $Million, 2020-2031
  • Figure 12.5: Global Flow Cytometry in Oncology Market (Academic and Research Institutions), $Million, 2020-2031
  • Figure 12.6: Global Flow Cytometry in Oncology Market (Other End Users), $Million, 2020-2031
  • Figure 13.1: Global Flow Cytometry in Oncology Market (by Region)
  • Figure 13.2: Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031
  • Figure 13.3: Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031
  • Figure 13.4: North America Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.5: North America: Market Dynamics
  • Figure 13.6: North America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
  • Figure 13.7: U.S. Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.8: Canada Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.9: North America Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 13.10: Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.11: Europe: Market Dynamics
  • Figure 13.12: Europe Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
  • Figure 13.13: Germany Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.14: U.K. Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.15: France Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.16: Italy Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.17: Spain Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.18: Netherlands Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.19: Rest-of-Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.20: Europe Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 13.21: Asia-Pacific Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.22: Asia-Pacific: Market Dynamics
  • Figure 13.23: APAC Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
  • Figure 13.24: China Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.25: Japan Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.26: India Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.27: Australia Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.28: South Korea Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.29: Singapore Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.30: RoAPAC Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.31: APAC Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 13.32: Latin America Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.33: Latin America: Market Dynamics
  • Figure 13.34: Latin America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
  • Figure 13.35: Brazil Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.36: Mexico Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.37: RoLA Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.38: LATAM Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 13.39: Rest-of-the-World Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.40: Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 14.1: Total Number of Companies Profiles
  • Figure 14.2: Agilent Technologies, Inc.: Product Portfolio
  • Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2018-2020
  • Figure 14.4: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
  • Figure 14.6: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 14.8: Apogee Flow Systems Ltd.: Product Portfolio
  • Figure 14.9: Apogee Flow Systems Ltd.: SWOT Analysis
  • Figure 14.10: Becton, Dickinson and Company: Product Portfolio
  • Figure 14.11: Becton, Dickinson and Company: Overall Financials, 2018-2020
  • Figure 14.12: Becton, Dickinson and Company: Revenue (by Segment), 2018-2020
  • Figure 14.13: Becton, Dickinson and Company: Revenue (by Region), 2018-2020
  • Figure 14.14: Becton, Dickinson and Company: R&D Expenditure, 2018-2020
  • Figure 14.15: Becton, Dickinson and Company: SWOT Analysis
  • Figure 14.16: bioAffinity Technologies, Inc.: Product Portfolio
  • Figure 14.17: bioAffinity Technologies, Inc.: SWOT Analysis
  • Figure 14.18: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 14.19: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
  • Figure 14.20: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.21: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
  • Figure 14.22: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.23: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 14.24: Bio-Techne Corporation: Product Portfolio
  • Figure 14.25: Bio-Techne Corporation: Overall Financials, 2018-2020
  • Figure 14.26: Bio-Techne Corporation: Revenue (by Segment), 2018-2020
  • Figure 14.27: Bio-Techne Corporation: Revenue (by Region), 2018-2020
  • Figure 14.28: Bio-Techne Corporation: R&D Expenditure, 2018-2020
  • Figure 14.29: Bio-Techne Corporation: SWOT Analysis
  • Figure 14.30: Cytek Biosciences: Product Portfolio
  • Figure 14.31: Cytek Biosciences: SWOT Analysis
  • Figure 14.32: Cytognos, S.L.: Product Portfolio
  • Figure 14.33: Cytognos, S.L.: SWOT Analysis
  • Figure 14.34: Danaher Corporation: Product Portfolio
  • Figure 14.35: Danaher Corporation: Overall Financials, 2018-2020
  • Figure 14.36: Danaher Corporation: Revenue (by Segment), 2018-2020
  • Figure 14.37: Danaher Corporation: Revenue (by Region), 2018-2020
  • Figure 14.38: Danaher Corporation: R&D Expenditure, 2018-2020
  • Figure 14.39: Danaher Corporation: SWOT Analysis
  • Figure 14.40: Miltenyi Biotec B.V. & Co. KG: Product Portfolio
  • Figure 14.41: Miltenyi Biotec B.V. & Co. KG: SWOT Analysis
  • Figure 14.42: Laboratory Corporation of America Holdings: Service Portfolio
  • Figure 14.43: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
  • Figure 14.44: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
  • Figure 14.45: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 14.46: Luminex Corporation: Product Portfolio
  • Figure 14.47: Luminex Corporation: Overall Financials, 2018-2020
  • Figure 14.48: Luminex Corporation: Revenue (by Segment), 2018-2020
  • Figure 14.49: Luminex Corporation: Revenue (by Region), 2018-2020
  • Figure 14.50: Luminex Corporation: R&D Expenditure, 2018-2020
  • Figure 14.51: Luminex Corporation: SWOT Analysis
  • Figure 14.52: NeoGenomics Laboratories, Inc.: Service Portfolio
  • Figure 14.53: NeoGenomics Laboratories, Inc.: Overall Financials, 2018-2020
  • Figure 14.54: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.55: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.56: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 14.57: Sony Corporation: Product Portfolio
  • Figure 14.58: Sony Corporation: Overall Financials, 2018-2020
  • Figure 14.59: Sony Corporation: Revenue (by Segment): 2018-2020
  • Figure 14.60: Sony Corporation: Revenue (by Region), 2018-2020 (E)
  • Figure 14.61: Sony Corporation: R&D Expenditure, 2018-2020 (E)
  • Figure 14.62: Sony Corporation: SWOT Analysis
  • Figure 14.63: Thermo Fisher Scientific, Inc.: Product Portfolio
  • Figure 14.64: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
  • Figure 14.65: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
  • Figure 14.66: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
  • Figure 14.67: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
  • Figure 14.68: Thermo Fisher Scientific Inc.: SWOT Analysis